Supercharged immune cells take on tough B-Cell cancers in early trial
NCT ID NCT03774654
First seen Jun 24, 2026 · Last updated Jul 14, 2026 · Updated 3 times
Summary
This early-phase trial tests a new cell therapy called ANCHOR for people with B-cell lymphoma or leukemia that has returned or not responded to treatment. The therapy uses immune cells from a healthy donor that are engineered to recognize and attack cancer cells carrying the CD19 marker, plus a boost to help them last longer. The main goals are to find a safe dose and watch for side effects, with a small group of 13 participants.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ANCHOR cells (engineered natural killer T-cells with a CD19-targeting chimeric antigen receptor and IL-15)
- What this could lead to
- If it works, this could point toward a new treatment option for people with hard-to-treat B-cell cancers that have not responded to standard therapies.
- What could go wrong
- This is a very early, small Phase 1 trial (13 participants) focused on safety, not proof of effectiveness. The cells may not last long enough or may cause serious side effects like cytokine release syndrome.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY B-CELL NON-HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Houston Methodist Hospital
Houston, Texas, 77030, United States
-
Texas Children's Hospital
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Engineered immune cells take aim at Hard-to-Treat childhood leukemia
- Immunotherapy combo shows promise for Tough-to-Treat blood cancers
- Engineered immune cells take on tough blood cancers in early trial
- New combo therapy shows promise for tough lymphoma cases
- Double-Barreled attack: stem cell transplant plus CAR-T shows promise for Hard-to-Treat lymphoma
- Supercharged immune cells take on tough lymphoma